Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned an average recommendation of “Buy” from the seventeen research firms that are presently covering the stock. Three analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $92.64.

A number of research firms recently issued reports on DXCM. Morgan Stanley cut DexCom from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $87.00 to $66.00 in a report on Tuesday, January 3rd. Robert W. Baird reaffirmed a “neutral” rating and issued a $79.00 price target on shares of DexCom in a report on Thursday, February 16th. B. Riley reaffirmed a “buy” rating and issued a $94.00 price target on shares of DexCom in a report on Monday, February 13th. Zacks Investment Research raised DexCom from a “sell” rating to a “hold” rating in a report on Monday, January 9th. Finally, Canaccord Genuity reissued a “buy” rating on shares of DexCom in a report on Tuesday, January 10th.

In other news, EVP Andrew K. Balo sold 3,200 shares of the business’s stock in a transaction dated Tuesday, January 10th. The stock was sold at an average price of $62.86, for a total transaction of $201,152.00. Following the completion of the transaction, the executive vice president now directly owns 109,545 shares in the company, valued at approximately $6,885,998.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $85.94, for a total value of $859,400.00. Following the transaction, the chief executive officer now owns 309,391 shares of the company’s stock, valued at $26,589,062.54. The disclosure for this sale can be found here. Insiders have sold a total of 122,265 shares of company stock valued at $9,393,117 over the last 90 days. Corporate insiders own 2.80% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Global X Management Co. LLC raised its position in shares of DexCom by 118.9% in the third quarter. Global X Management Co. LLC now owns 1,900 shares of the medical device company’s stock valued at $167,000 after buying an additional 1,032 shares in the last quarter. Accredited Investors Inc. acquired a new position in shares of DexCom during the third quarter valued at about $207,000. Redmile Group LLC acquired a new position in shares of DexCom during the third quarter valued at about $216,000. First Allied Advisory Services Inc. acquired a new position in shares of DexCom during the fourth quarter valued at about $218,000. Finally, Private Bank & Trust Co. acquired a new position in shares of DexCom during the third quarter valued at about $220,000.

DexCom (NASDAQ:DXCM) opened at 79.62 on Thursday. DexCom has a one year low of $57.68 and a one year high of $96.38. The firm’s market capitalization is $6.75 billion. The firm has a 50 day moving average of $79.38 and a 200 day moving average of $76.93.

Your IP Address:

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.